Source: Lancet April 17, 2019
Excerpt: An Advisory Group of 29 scientists from 18 countries met in March, 2019, to recommend priorities for the International Agency for Research on Cancer (IARC) Monographs programme during 2020–24. IARC periodically convenes such advisory groups to ensure that the Monographs evaluations reflect the current state of scientific evidence relevant to carcinogenicity.
A detailed report of the Advisory Group will be published subsequently.
The Advisory Group recommended a broad range of agents with high(table 1), medium, or low (table 2)
priority for evaluation. Priority was assigned on the basis of evidence of human exposure and the extent
of available evidence for evaluating carcinogenicity (ie, the availability of relevant human cancer, experimental animal bioassay, or mechanistic evidence to support a new or updated evaluation according to the Preamble to the IARC Monographs 1).
For previously evaluated agents, the Advisory Group considered the basis of the previous classification, as well as the potential impact of the newly available evidence during integration across streams (see table 4 in Preamble to the IARC Monographs 1).
TABLE 1: Agents Recommended for Evaluation by the IARC Monographs with High Priority
Table credit: www.thelancet.com/oncology Published online April 17, 2019 http://dx.doi.org/10.1016/S1470-2045(19)30246-3
IARC is to review the carcinogenicity of RF radiation in the second half of the 2020–24 period